Port Hueneme Cbc Base, CA, United States
Port Hueneme Cbc Base, CA, United States

Time filter

Source Type

News Article | May 9, 2017
Site: www.prnewswire.com

"In the second quarter, we delivered on a number of strategic objectives, including expanding our opportunities for growth," said Stellar President and CEO Frank Oakes. "We continue to closely monitor the progress of our customers as they generate the next set of clinical results and inflection points for our business." Stellar Chief Financial Officer Kathi Niffenegger reported that expenditures for the first half of fiscal year 2017 were in line with management's expectations and included additional investments to increase the scalability and throughput capacity of the company's KLH production and manufacturing processes. "Our spending in the first half of fiscal 2017 reflects our focus on managing upfront development costs and capital expenditures while investing in the people, processes and resources we need to meet our customers' near and long-term product forecasts," she said. Total revenues were $0.06 million for the quarter ended March 31, 2017 compared to $0.33 million for same period last year. The change was due to a decrease in product sales volume. While the company's customer base has not changed significantly, product sales volumes are subject to variability associated with the rate of development and progression of clinical studies of third-party products that utilize Stellar KLH. For the three months ended March 31, 2017, product sales consisted of lower volume orders for pre-clinical studies and immune system assays. For the three months ended March 31, 2016, product sales primarily consisted of higher volume orders for later stage clinical studies. The rate of progression towards later stage studies is expected to continue to affect the timing and volume of future product sales. Total expenses decreased by $0.21 million to $1.21 million for the quarter ended March 31, 2017 compared to $1.42 million for the same period last year. For the quarter ended March 31, 2017, Stellar reported a net loss of $1.10 million, or $0.11 per basic share, compared to a net loss of $0.86 million, or $0.10 per basic share, for the same period last year. Total revenues were $0.20 million for the six months ended March 31, 2017 compared to $0.81 million for the same period last year. The change was primarily due to a decrease in product sales. While the company's customer base has not changed significantly, product sales volumes are subject to variability associated with the rate of development and progression of clinical studies of third-party products that utilize Stellar KLH. For the six months ended March 31, 2017, product sales consisted of KLH for clinical and pre-clinical studies and immune system assays. For the six months ended March 31, 2016, product orders primarily consisted of higher volume orders for later stage clinical studies. Total revenues were also impacted by a decrease in the number of significant customers who purchased the company's products and services, with two customers representing 88% of total revenue for the current period compared to five customers representing 90% of total revenue for the same period last year. Total expenses decreased by $0.45 million to $2.77 million for the six months ended March 31, 2017 compared to $3.22 million for the same period last year. For the first half of fiscal year 2017, Stellar reported a net loss of $2.59 million, or $0.26 per basic share, compared to a net loss of $2.49 million, or $0.30 per basic share, for the same period last year. At March 31, 2017, the company had working capital of approximately $8.92 million. Cash, cash equivalents and short-term investments totaled $8.60 million. Stellar will file its Form 10-Q for the quarter ended March 31, 2017 with the Securities and Exchange Commission on May 9, 2017. To view the company's filings, please visit the website of the Securities and Exchange Commission at www.sec.gov. To view the company's filings with the Canadian Securities Administrators (CSA), including the Management Discussion and Analysis and related consolidated financial statements, please visit the CSA's SEDAR website at www.sedar.com. Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar KLH is a trademark of Stellar Biotechnologies. This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental regulations and the ability or failure to comply with governmental regulations; changes in trade policy and international law; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stellar-biotechnologies-reports-second-quarter-2017-financial-results-300454326.html


This report studies the Keyhole Limpet Hemocyanin (KLH) market, KLH, which can be used as an active pharmaceutical ingredient (“API”), is a very large, high molecular weight, oxygen-carrying glycoprotein made of millions of atoms. There are two KLH subunit forms, KLH1 and KLH2, each composed of seven or eight functional units, with each functional unit having an oxygen binding site of two copper atoms. Keyhole limpet hemocyanin is an extremely large, heterogeneous glycosylated protein consisting of subunits with a molecular weight of 350,000 and 390,000 in aggregates with molecular weights of 4,500,000-13,000,000. Each domain of a KLH subunit contains two copper atoms that together bind a single oxygen molecule (O2). The KLH protein is potently immunogenic yet safe in humans and is therefore highly prized as a vaccine carrier protein. For more information or any query mail at sales@wiseguyreports.com This report focuses on the Keyhole Limpet Hemocyanin (KLH) in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Columbia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Applications, can be divided into Laboratory Pharmaceuticals There are 15 Chapters to deeply display the global Keyhole Limpet Hemocyanin (KLH) market. Chapter 2, to analyze the top manufacturers of Keyhole Limpet Hemocyanin (KLH), with sales, revenue, and price of Keyhole Limpet Hemocyanin (KLH), in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; 1 Market Overview 1.1 Keyhole Limpet Hemocyanin (KLH) Introduction 1.2 Market Analysis by Type 1.2.1 GMP/Clinic Grade 1.2.2 Research Grade 1.3 Market Analysis by Applications 1.3.1 Laboratory 1.3.2 Pharmaceuticals 1.4 Market Analysis by Regions 1.4.1 North America (USA, Canada and Mexico) 1.4.1.1 USA Market States and Outlook (2012-2022) 1.4.1.2 Canada Market States and Outlook (2012-2022) 1.4.1.3 Mexico Market States and Outlook (2012-2022) 1.4.2 Europe (Germany, France, UK, Russia and Italy) 1.4.2.1 Germany Market States and Outlook (2012-2022) 1.4.2.2 France Market States and Outlook (2012-2022) 1.4.2.3 UK Market States and Outlook (2012-2022) 1.4.2.4 Russia Market States and Outlook (2012-2022) 1.4.2.5 Italy Market States and Outlook (2012-2022) 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 1.4.3.1 China Market States and Outlook (2012-2022) 1.4.3.2 Japan Market States and Outlook (2012-2022) 1.4.3.3 Korea Market States and Outlook (2012-2022) 1.4.3.4 India Market States and Outlook (2012-2022) 1.4.3.5 Southeast Asia Market States and Outlook (2012-2022) 1.4.4 South America, Middle East and Africa 1.4.4.1 Brazil Market States and Outlook (2012-2022) 1.4.4.2 Egypt Market States and Outlook (2012-2022) 1.4.4.3 Saudi Arabia Market States and Outlook (2012-2022) 1.4.4.4 South Africa Market States and Outlook (2012-2022) 1.4.4.5 Nigeria Market States and Outlook (2012-2022) 1.5 Market Dynamics 1.5.1 Market Opportunities 1.5.2 Market Risk 1.5.3 Market Driving Force 2 Manufacturers Profiles 2.1 biosyn Corporation 2.1.1 Business Overview 2.1.2 Keyhole Limpet Hemocyanin (KLH) Type and Applications 2.1.2.1 Type 1 2.1.2.2 Type 2 2.1.3 biosyn Corporation Keyhole Limpet Hemocyanin (KLH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.2 Stellar Biotechnologies 2.2.1 Business Overview 2.2.2 Keyhole Limpet Hemocyanin (KLH) Type and Applications 2.2.2.1 Type 1 2.2.2.2 Type 2 2.2.3 Stellar Biotechnologies Keyhole Limpet Hemocyanin (KLH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.3 Sigma-Aldrich Fine Chemicals 2.3.1 Business Overview 2.3.2 Keyhole Limpet Hemocyanin (KLH) Type and Applications 2.3.2.1 Type 1 2.3.2.2 Type 2 2.3.3 Sigma-Aldrich Fine Chemicals Keyhole Limpet Hemocyanin (KLH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.4 Thermo-Fisher Scientific 2.4.1 Business Overview 2.4.2 Keyhole Limpet Hemocyanin (KLH) Type and Applications 2.4.2.1 Type 1 2.4.2.2 Type 2 2.4.3 Thermo-Fisher Scientific Keyhole Limpet Hemocyanin (KLH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.5 G-Biosciences 2.5.1 Business Overview 2.5.2 Keyhole Limpet Hemocyanin (KLH) Type and Applications 2.5.2.1 Type 1 2.5.2.2 Type 2 2.5.3 G-Biosciences Keyhole Limpet Hemocyanin (KLH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 3 Global Keyhole Limpet Hemocyanin (KLH) Market Competition, by Manufacturer 3.1 Global Keyhole Limpet Hemocyanin (KLH) Sales and Market Share by Manufacturer 3.2 Global Keyhole Limpet Hemocyanin (KLH) Revenue and Market Share by Manufacturer 3.3 Market Concentration Rate 3.3.1 Top 3 Keyhole Limpet Hemocyanin (KLH) Manufacturer Market Share 3.3.2 Top 6 Keyhole Limpet Hemocyanin (KLH) Manufacturer Market Share 3.4 Market Competition Trend For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


News Article | May 31, 2017
Site: www.prnewswire.com

The company will provide a review of its Stellar KLH business and recent corporate activities. Stellar senior management will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with Stellar should contact Marcum conference coordinators to arrange an appointment. For more information regarding the Marcum conference visit: www.marcummicrocap.com. About Stellar Biotechnologies Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar KLH is a trademark of Stellar Biotechnologies. Stellar Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental regulations and the ability or failure to comply with governmental regulations; changes in trade policy and international law; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stellar-biotechnologies-to-present-at-marcum-investor-conference-300465720.html


SAN FRANCISCO, CA--(Marketwired - March 02, 2017) - Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Included in this interview is: Stellar Biotechnologies Inc. ( : SBOT) TLSR: Would you talk about a company you follow that has a novel niche in vaccine research and production? JM: I follow Stellar Biotechnologies Inc., which produces keyhole limpet hemocyanin (KLH). This carrier protein is being evaluated as an immune modulating agent in a number of vaccine trials. TLSR: Would you explain what is special about KLH? JM: If you want to make a vaccine, it's very difficult. You often can't just vaccinate with a small molecule by itself, even with an adjuvant it's difficult. Many times that antigen may need to be linked to carrier protein for presentation to the immune system to generate the appropriate immune response, and that's what KLH does. KLH is special in that it's a tremendously big protein. It has a lot of amine groups on it so you can hook a lot of things up to it. And the KLH itself is very immunogenic. So KLH can actually stimulate its own immune response and actually help generate antigen-specific responses almost by default just by being the carrier protein. The KLH itself will tend to play a role in generating immune responses to your antigen. When you're developing a vaccine for any indication, you can have a dendritic cell vaccine, you can have a DNA-based vaccine, you can have a KLH-based vaccine or a peptide vaccine, and each one has its own advantages, disadvantages and attributes that you may or may not want as part of the immune response you are targeting. KLH seems to be geared toward generating antibody responses versus T-cell responses. So when you're trying to target something like lupus and you're trying to take out all of the interferon cytokines that are floating around and driving unwanted hyperinflammation, neutralizing antibodies might be an ideal approach. And an ideal approach for generating lots and lots of neutralizing antibodies is to use a KLH-based vaccine. TLSR: How is Stellar producing KLH, and how is that different from others? JM: What is unique from a Stellar perspective is that the company has on-land aquaculture. It is producing a very consistent KLH product from the keyhole limpet animals, whereas others rely on harvesting those animals from the ocean. There are only a few spots in the world off the coast of California where you could do that. And there's a lot of variability in the KLH product by harvesting off the ocean floor whereas Stellar does it in a very consistent, very reproducible process. Part of the challenge with KLH is that it's such a big protein that you can't make a recombinant KLH, which is why you need the sophisticated aquaculture facility that only Stellar has to generate sufficient quantities to make a reproducible ingredient that could be used for vaccines. Continue reading this interview: Stellar Biotechnologies (NASDAQ: SBOT) Could Rise with KLH Vaccine Trial Success Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. The following companies mentioned in this interview are billboard sponsors of Streetwise Reports: Stellar Biotechnologies Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Jason McCarthy: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: None. I, or members of my immediate household or family, are paid by the following companies mentioned in this article: None. My company has a financial relationship with the following companies mentioned in this interview: Stellar Biotechnologies and Neovacs. I determined which companies would be included in this article based on my research and understanding of the sector. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview. Please see the end of the interview for the complete disclosure: Stellar Biotechnologies (NASDAQ: SBOT) Could Rise with KLH Vaccine Trial Success


Paris et Boston, le 7 décembre 2016 - NEOVACS (Alternext Paris : ALNEV), leader de l'immunothérapie active pour le traitement des maladies auto-immunes, annonce aujourd'hui avoir obtenu le statut « Fast-Track » de la Food and Drug Administration (FDA), pour l'IFNalpha Kinoïde dans le traitement du Lupus, le vaccin thérapeutique le plus avancé, issu de la recherche de Néovacs. La désignation « Fast-Track » mise en place par la FDA est réservée aux thérapies en développement qui ciblent des maladies sévères, mettent en jeu le pronostic vital et ayant montré avec des données cliniques leur aptitude à répondre à un besoin médical insatisfait. Ce statut facilite les échanges avec la FDA, permet d'accélérer le développement du produit et de bénéficier d'un examen prioritaire du dossier d'enregistrement. Grâce à cette désignation « Fast-Track », Néovacs réunit désormais les conditions nécessaires pour permettre un accès plus rapide de l'IFNalpha Kinoïde pour les patients aux États-Unis. Pour rappel, Néovacs mène actuellement une étude clinique de phase IIb internationale (étude IFN-K-002) dans le lupus érythémateux systémique (LES), une maladie auto-immune, chronique et invalidante, pour laquelle les traitements standards n'offrent pas de bénéfices thérapeutiques satisfaisants aux patients. L'objectif de cette étude est d'évaluer l'efficacité biologique et clinique de l'IFNalpha Kinoïde chez des patients atteints de forme modérée à sévère du LES. L'essai, en cours de recrutement, inclura 178 patients dans 21 pays en Amérique latine, Asie, Europe et aux Etats-Unis. À propos de la technologie Kinoïde développée par Néovacs  Elle vise le traitement de pathologies associées à une surproduction d'une cytokine endogène. Cette technologie relève de l'immunothérapie active et est basée sur la génération d'une réponse immunitaire grâce à l'administration d'un complexe immunogène associant la cytokine ciblée (par exemple l'IFNalpha, fabriquée par 3P Biopharmaceuticals) à une protéine porteuse (par exemple la KLH, produite par notre partenaire Stellar Biotechnologies). L'injection intramusculaire de ce Kinoïde au patient va permettre d'induire la réponse immunitaire et de stimuler la production d'anticorps polyclonaux dirigés contre la cytokine cible. On parvient ainsi à bloquer la surproduction de la cytokine et ses effets biologiques. Plusieurs pathologies auto-immunes et inflammatoires (lupus érythémateux systémique, dermatomyosite et diabète de type 1.) se caractérisent par un dérèglement du fonctionnement de cytokines (IFNalpha) qui se retrouvent produites en excès. Cette surproduction va favoriser l'inflammation et la dérégulation de l'immunité. À propos de Néovacs Cotée sur Alternext Paris depuis 2010, Néovacs est devenu un acteur majeur dans les vaccins thérapeutiques ciblant le traitement des maladies auto-immunes et/ou inflammatoires. Grâce à sa technologie innovante induisant une réponse immunitaire polyclonale, protégée potentiellement jusqu'en 2032 par 5 familles de brevets, Néovacs concentre ses efforts de développement clinique sur l'IFNalpha-Kinoïde pour le traitement du lupus et de la dermatomyosite. Néovacs réalise également des travaux précliniques sur d'autres vaccins thérapeutiques pour le traitement des maladies auto-immunes, cancers, allergies et diabète de type 1. L'ambition de cette « approche Kinoïde » est de permettre aux patients de mieux supporter un traitement à vie qui serait plus efficace, bien toléré et très souple dans son administration. Néovacs est éligible au plan PEA-PME. Pour plus d'information sur Néovacs, visitez le site web : http://neovacs.fr/


News Article | March 1, 2017
Site: www.prnewswire.com

LOS ANGELES, March 1, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy development pipelines, and biopharmaceuticals manufacturer Amaran Biotechnology, Inc., have entered into an exclusive multi-year...


News Article | October 28, 2016
Site: www.marketwired.com

LOS ANGELES, CA--(Marketwired - Oct 24, 2016) - Stellar Biotechnologies, Inc. ( : SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, announced today that Gregory T. Baxter, PhD, will join the company's management team in the new role of Executive Vice President of Corporate Development, effective December 1, 2016. Dr. Baxter, a current member of Stellar's Board of Directors and its Scientific Advisory Board, will lead the company's corporate development activities, including joint ventures and business development, as well as the expansion of Stellar's production and manufacturing capabilities. Stellar previously announced the development of a second production site in Baja California, Mexico and a joint venture, Neostell S.A.S., with French partner Neovacs S.A. for manufacturing immunotherapy products for Neovacs and potentially other third-party customers utilizing KLH-based therapeutic vaccines. "Greg's in-depth understanding of our business and extensive business experience in biotechnology, pharmaceutical drug development and aquaculture make him a uniquely qualified choice to support our growth opportunities," said Stellar President and CEO Frank Oakes. "He will take the lead oversight role in our Neostell joint venture and guide our strategic planning and operations." Dr. Baxter is a published author and holds over 20 patents on various aspects of molecular biology and biochemistry, and has served as an executive and scientist for several biotechnology corporations and foundations. Since 2001, he has been a Senior Scientist in the Department of Clinical Drug Development for CCS Associates, Inc. He also serves as Adjunct Associate Professor at Cornell University in the College of Chemical Engineering and on the Founders Board of Stanford University's StartX Med Program. Dr. Baxter's background spans both science and business arenas including Program Director for the National Science Foundation (NSF) Division of Industrial Innovation and Partnerships; Founder and CSO of Hurel Corporation; Founder and CEO of Aegen Biosciences; and Research Scientists for Molecular Devices Corporation. Dr. Baxter received his PhD in Biochemistry/Molecular Biology from the University of California, Santa Barbara. Dr. Baxter said that Stellar provides an exciting opportunity to work in a pivotal area for multiple indications. "KLH-conjugated vaccines have demonstrated great promise and our collaborators have a number of exciting clinical milestones ahead. I look forward to advancing the sustainable production and manufacturing of GMP-grade KLH and paving the way for more KLH-based approaches to immunotherapy," he said. About Stellar Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. ( : SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; governmental regulations and the ability or failure to comply with governmental regulations; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to the Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.


News Article | December 9, 2016
Site: www.marketwired.com

LOS ANGELES, CA--(Marketwired - Dec 9, 2016) - Stellar Biotechnologies, Inc. ( : SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced the appointment of Charles V. Olson, D.Sc. and Paul Chun to the company's Board of Directors. "Dr. Olson's and Mr. Chun's appointment to our Board comes at an exciting time as we prepare to expand our production capabilities to support a growing list of active immunotherapies utilizing our Stellar KLH protein. Their combined expertise in pharmaceutical development and commercialization and capital markets will be a valuable resource to Stellar and its shareholders," said Stellar President and CEO Frank Oakes. Dr. Olson has been a member of Stellar's scientific advisory board since June 2014 and has extensive scientific, manufacturing and senior management experience in the biotechnology and pharmaceutical industries. He is currently Chief Technology Officer at Anthera Pharmaceuticals, Inc. and is a Principal Biotechnology Consultant for Compass Biotechnology LLC. "Having had the opportunity to work closely with Stellar's technology developers and management now for more than two years, I am looking to helping Stellar continue to position KLH as the go-to molecule for a broad spectrum of indications and markets," said Dr. Olson. Mr. Chun is Managing Partner and founder of Eldred Advisors LLC, an advisory firm specializing in the life sciences. Mr. Chun brings broad experience as an investment analyst and strategic advisor to the Board, including expertise in therapeutics development and commercialization, corporate development, strategy and finance. His previous work includes roles at Goldman, Sachs & Co., Tavistock Life Sciences Co., Amgen, Inc., and Westwicke Partners, LLC. "The immunotherapy landscape continues to evolve at a rapid pace, and I am excited to work with the Stellar team as the company expands upon the distinct role it can play in the space," said Mr. Chun. About Stellar Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. ( : SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar KLH is a trademark of Stellar Biotechnologies. Stellar Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental regulations and the ability or failure to comply with governmental regulations; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to the Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.


News Article | December 12, 2016
Site: www.marketwired.com

LOS ANGELES, CA--(Marketwired - Dec 12, 2016) - Stellar Biotechnologies, Inc. ( : SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, will host a conference call and live webcast on Thursday, December 15, 2016 at 1:30 p.m. ET (10:30 a.m. PT) to discuss its fiscal year 2016 results and to provide an update on its business. To access the webcast of the conference call, go to: https://www.webcaster4.com/Webcast/Page/1359/18766. Questions for management may be submitted via the chat feature of the live online webcast. Audio of the live teleconference is available by dialing (913) 312-1489. Passcode is 2812115. An audio replay of the call will be available shortly after the conclusion of the live call, and remain available on the Stellar website for 30 days. About Stellar Biotechnologies  Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. ( : SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar KLH is a trademark of Stellar Biotechnologies. Stellar Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; anticipated requirements for operating capital; governmental regulations and the ability or failure to comply with governmental regulations; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to the Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.


News Article | December 1, 2016
Site: www.marketwired.com

LOS ANGELES, CA--(Marketwired - Dec 1, 2016) - Stellar Biotechnologies, Inc. ( : SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual LD Micro Main Event investor conference to be held December 6-8, 2016 in Los Angeles, California. The company will provide a review of its Stellar KLH™ business and recent corporate activities. Stellar senior management will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with Stellar should contact LD Micro Conference coordinators to arrange an appointment. For more information regarding the LD Micro Main Event visit: http://www.ldmicro.com/events. About Stellar Based north of Los Angeles at the Port of Hueneme, Stellar Biotechnologies, Inc. ( : SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar is unique in its proprietary methods, facilities, and KLH technology. The company is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Stellar Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; governmental regulations and the ability or failure to comply with governmental regulations; the timing of Stellar's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of Stellar's joint ventures and strategic partnerships; and other factors referenced in Stellar's filings with securities regulators. For a discussion of further risks and uncertainties related to the Stellar's business, please refer to the Stellar's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Stellar assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.

Loading Stellar Biotechnologies collaborators
Loading Stellar Biotechnologies collaborators